A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPD
Public ClinicalTrials.gov record NCT01525615. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Determine the Effect of 12 Weeks Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (2.5/5 µg and 5/5 µg) Delivered by the Respimat® Inhaler, on Exercise Endurance Time During Constant Work Rate Cycle Ergometry in Patients With Chronic Obstructive Pulmonary Disease (COPD)[Torracto (TM)]
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to compare the effects of orally inhaled tiotropium + olodaterol fixed dose combination (2.5/5 µg; 5/5 µg) with placebo on exercise tolerance after 12 weeks of treatment in patients with COPD.
Study identification
- NCT ID
- NCT01525615
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 404 participants
Conditions and interventions
Conditions
Interventions
- Respimat inhaler Device
- tiotropium+olodaterol (low dose) Drug
- tiotropium + olodaterol (high dose) Drug
- placebo to tiotropium+olodaterol Drug
Device · Drug
Eligibility (public fields only)
- Age range
- 40 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 2012 (Type not available)
- Primary completion
- Sep 2013 (Actual)
- Completion
- Sep 2013 (Actual)
- Last update posted
- Aug 29, 2016
2012 – 2013
United States locations
- U.S. sites
- 15
- U.S. states
- 11
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1237.15.01503 Boehringer Ingelheim Investigational Site | Torrance | California | — | — |
| 1237.15.01512 Boehringer Ingelheim Investigational Site | Hartford | Connecticut | — | — |
| 1237.15.01506 Boehringer Ingelheim Investigational Site | Springfield | Illinois | — | — |
| 1237.15.01507 Boehringer Ingelheim Investigational Site | Iowa City | Iowa | — | — |
| 1237.15.01504 Boehringer Ingelheim Investigational Site | Livonia | Michigan | — | — |
| 1237.15.01511 Boehringer Ingelheim Investigational Site | Saint Charles | Missouri | — | — |
| 1237.15.01509 Boehringer Ingelheim Investigational Site | Lebanon | New Hampshire | — | — |
| 1237.15.01513 Boehringer Ingelheim Investigational Site | Charlotte | North Carolina | — | — |
| 1237.15.01514 Boehringer Ingelheim Investigational Site | Philadelphia | Pennsylvania | — | — |
| 1237.15.01516 Boehringer Ingelheim Investigational Site | Pittsburgh | Pennsylvania | — | — |
| 1237.15.01508 Boehringer Ingelheim Investigational Site | Easley | South Carolina | — | — |
| 1237.15.01501 Boehringer Ingelheim Investigational Site | Greenville | South Carolina | — | — |
| 1237.15.01505 Boehringer Ingelheim Investigational Site | Spartanburg | South Carolina | — | — |
| 1237.15.01502 Boehringer Ingelheim Investigational Site | Union | South Carolina | — | — |
| 1237.15.01510 Boehringer Ingelheim Investigational Site | Richmond | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 45 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01525615, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 29, 2016 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01525615 live on ClinicalTrials.gov.